Milan, Italy and Taicang, China — September 9, 2026 — Nerviano Medical Sciences S.r.l. (“NMS”), a global oncology-focused biopharmaceutical company, and HiDiamond Biotechnology Co., Ltd. (“HiDiamond”), a specialist in innovative NCEs therapeutics, today announced a collaboration and license agreement for NMS-173.
NMS-173 is a highly potent, second-generation dual inhibitor of mutant Isocitrate Dehydrogenase 1 and 2 (mIDH1/2). Unlike first-generation reversible inhibitors, NMS-173 utilizes a covalent mechanism of action designed to achieve sustained target inhibition and potentially address resistance mechanisms associated with existing reversible inhibitors.